mutLBSgeneDB

mutLBSgeneDB
mutated Ligand Binding Site gene DataBase

Home

Download

 Statistics

Help

About Us
Bioinformatics and Systems Medicine Laboratory Bioinformatics and Systems Medicine Laboratory

Gene Summary

Ligand Binding Site Mutation Information

Protein Structure Related Information

Gene Expression and Gene-Gene Network

Phenotype Information

Pharmacological Information

Conservation Information for LBS

Gene summary for MAPK10
Gene summary
Basic gene Info.Gene symbolMAPK10
Gene namemitogen-activated protein kinase 10
SynonymsJNK3|JNK3A|PRKM10|SAPK1b|p493F12|p54bSAPK
CytomapUCSC genome browser: 4q22.1-q23
Type of geneprotein-coding
RefGenesNM_002753.3,
NM_138980.2,NM_138981.2,NM_138982.2,
DescriptionJNK3 alpha protein kinaseMAP kinase 10MAP kinase p49 3F12MAPK 10c-Jun N-terminal kinase 3stress activated protein kinase betastress-activated protein kinase 1bstress-activated protein kinase JNK3
Modification date20141207
dbXrefs MIM : 602897
HGNC : HGNC
Ensembl : ENSG00000109339
HPRD : 04207
Vega : OTTHUMG00000130604
ProteinUniProt: P53779
go to UniProt's Cross Reference DB Table
ExpressionCleanEX: HS_MAPK10
BioGPS: 5602
PathwayNCI Pathway Interaction Database: MAPK10
KEGG: MAPK10
REACTOME: MAPK10
Pathway Commons: MAPK10
ContextiHOP: MAPK10
ligand binding site mutation search in PubMed: MAPK10
UCL Cancer Institute: MAPK10
Assigned class in mutLBSgeneDBB: This gene belongs to targetable_mutLBSgenes.

Gene ontology having evidence of Inferred from Direct Assay (IDA) from Entrez
GO IDGO TermPubMed ID


Top
Ligand binding site mutations for MAPK10

Cancer type specific mutLBS sorted by frequency
LBSAAchange of nsSNVCancer type# samples
A80A81VBRCA1
N152,C154L153VCOAD1
L206K204ECOAD1
L95S96RCOAD1
Y171M173TCOAD1
I124I124FCOAD1
E111,M115V113IHNSC1
A91,N89V90LLUAD1
E367A366VSKCM1
A91A91TSTAD1
N89D87GSTAD1
A80A81VSTAD1
D207D207GSTAD1
M115L114VTHCA1
Q75Q75HUCEC1
E367E367KUCEC1
cf) Cancer type abbreviation. BLCA: Bladder urothelial carcinoma, BRCA: Breast invasive carcinoma, CESC: Cervical squamous cell carcinoma and endocervical adenocarcinoma, COAD: Colon adenocarcinoma, GBM: Glioblastoma multiforme, LGG: Brain lower grade glioma, HNSC: Head and neck squamous cell carcinoma, KICH: Kidney chromophobe, KIRC: Kidney renal clear cell carcinoma, KIRP: Kidney renal papillary cell carcinoma, LAML: Acute myeloid leukemia, LUAD: Lung adenocarcinoma, LUSC: Lung squamous cell carcinoma, OV: Ovarian serous cystadenocarcinoma, PAAD: Pancreatic adenocarcinoma, PRAD: Prostate adenocarcinoma, SKCM: Skin cutaneous melanoma, STAD: Stomach adenocarcinoma, THCA: Thyroid carcinoma, UCEC: Uterine corpus endometrial carcinoma.


Top
Protein structure related information for MAPK10
Relative protein structure stability change (ΔΔE) using Mupro 1.1
Mupro score denotes assessment of the effect of mutations on thermodynamic stability.
  (ΔΔE<0: mutation decreases stability, ΔΔE>0: mutation increases stability)
: nsSNV at non-LBS: nsSNV at LBS

nsSNVs sorted by the relative stability change of protein structure by each mutation
Blue: mutations of positive stability change. and red : the most recurrent mutation for this gene.
LBSAAchange of nsSNVRelative stability change
Y171M173T-1.5971827
M115L114V-1.4589382
D207D207G-1.1273875
I124I124F-1.0099822
E367E367K-0.99635203
N152L153V-0.75550811
C154L153V-0.75550811
A80A81V-0.71749036
N89D87G-0.67184702
A91A91T-0.66505324
L95S96R-0.54291663
L206K204E-0.53810211
E111V113I-0.53529644
M115V113I-0.53529644
E367A366V-0.51460518
Q75Q75H-0.41779785
A91V90L-0.22657988
N89V90L-0.22657988
(MuPro1.1: Jianlin Cheng et al., Prediction of Protein Stability Changes for Single-Site Mutations Using Support Vector Machines, PROTEINS: Structure, Function, and Bioinformatics. 2006, 62:1125-1132)

Structure image for MAPK10 from PDB

Top
Differential gene expression and gene-gene network for MAPK10
Differential gene expression between mutated and non-mutated LBS samples in all 16 major cancer types

Differential co-expressed gene network based on protein-protein interaction data (CePIN)
* Left PPI network was created from samples with mutations in the LBS of MAPK10 and the right PPI network was created from samples without mutations in the LBS of MAPK10. Only genes with p-value < 0.05 are shown.
Red circle: input gene. Orange circle: LBSgene. Blue circle: other gene.


Top

Top
Phenotype information for MAPK10
Gene level disease information (DisGeNet)
Disease IDDisease name# PubMedAssociation type

Mutation level pathogenic information (ClinVar annotation)
Allele IDAA changeClinical significanceOriginPhenotype IDs

Top
Pharmacological information for MAPK10
Gene expression profile of anticancer drug treated cell-lines (CCLE)
Heatmap showing the correlation between gene expression and drug response across all the cell-lines. We chose the top 20 among 138 drugs.We used Pearson's correlation coefficient.

Gene-centered drug-gene interaction network
Drug information targeting mutLBSgene (Approved drugs only)
Drug statusDrugBank IDNameTypeDrug structure
ExperimentalDB017822,6-Dihydroanthra/1,9-Cd/Pyrazol-6-OneSmall molecule
ExperimentalDB02388Cyclohexyl-{4-[5-(3,4-Dichlorophenyl)-2-Piperidin-4-Yl-3-Propyl-3h-Imidazol-4-Yl]-Pyrimidin-2-Yl}AmineSmall molecule
ExperimentalDB03084Cyclopropyl-{4-[5-(3,4-Dichlorophenyl)-2-[(1-Methyl)-Piperidin]-4-Yl-3-Propyl-3h-Imidazol-4-Yl]-Pyrimidin-2-Yl}AmineSmall molecule
ExperimentalDB036239-(4-Hydroxyphenyl)-2,7-PhenanthrolineSmall molecule
ExperimentalDB04395Phosphoaminophosphonic Acid-Adenylate EsterSmall molecule
ExperimentalDB06933N-(tert-butyl)-4-[5-(pyridin-2-ylamino)quinolin-3-yl]benzenesulfonamideSmall molecule
ExperimentalDB07010N-BENZYL-4-[4-(3-CHLOROPHENYL)-1H-PYRAZOL-3-YL]-1H-PYRROLE-2-CARBOXAMIDESmall molecule
ExperimentalDB07217N-(3-cyano-4,5,6,7-tetrahydro-1-benzothien-2-yl)-2-fluorobenzamideSmall molecule
ExperimentalDB080054-{[5-chloro-4-(1H-indol-3-yl)pyrimidin-2-yl]amino}-N-ethylpiperidine-1-carboxamideSmall molecule
ExperimentalDB08010(3Z)-1-[(6-fluoro-4H-1,3-benzodioxin-8-yl)methyl]-4-[(E)-2-phenylethenyl]-1H-indole-2,3-dione 3-oximeSmall molecule
ExperimentalDB08011(3E)-5-fluoro-1-[(6-fluoro-4H-1,3-benzodioxin-8-yl)methyl]-1H-indole-2,3-dione 3-oximeSmall molecule
ExperimentalDB08015(3Z)-1-[(6-fluoro-4H-1,3-benzodioxin-8-yl)methyl]-4-phenyl-1H-indole-2,3-dione 3-oximeSmall molecule
ExperimentalDB080215-bromo-N-(3-chloro-2-(4-(prop-2-ynyl)piperazin-1-yl)phenyl)furan-2-carboxamideSmall molecule
ExperimentalDB08023N-cyclohexyl-4-imidazo[1,2-a]pyridin-3-yl-N-methylpyrimidin-2-amineSmall molecule
ExperimentalDB08025N-{2'-[(4-FLUOROPHENYL)AMINO]-4,4'-BIPYRIDIN-2-YL}-4-METHOXYCYCLOHEXANECARBOXAMIDESmall molecule
ExperimentalDB080262-{4-[(4-imidazo[1,2-a]pyridin-3-ylpyrimidin-2-yl)amino]piperidin-1-yl}-N-methylacetamideSmall molecule
ExperimentalDB085551-(3-bromophenyl)-7-chloro-6-methoxy-3,4-dihydroisoquinolineSmall molecule

Gene-centered ligand-gene interaction network

Ligands binding to mutated ligand binding site of MAPK10 go to BioLip
Ligand IDLigand short nameLigand long namePDB IDPDB namemutLBS
33AN-BENZYL-4-[4-(3-CHLOROPHENYL)-1H-PYRAZOL-3-YL]-1H-PYRROLE-2-CARBOXAMIDE2ok1AA80 A91 L206
4464-[(4-{[6-BROMO-3-(METHOXYCARBONYL)-1-OXO-4-PHENYLISOQUINOLIN-2(1H)-YL]METHYL}PHENYL)AMINO]-4-OXOBUTANOIC ACID2zduAA80 A91 N152 L206
255N-(TERT-BUTYL)-4-[5-(PYRIDIN-2-YLAMINO)QUINOLIN-3-YL]BENZENESULFONAMIDE2r9sAA80 N89 A91 I124 N152 L206
JNO2-{4-[(4-IMIDAZO[1,2-A]PYRIDIN-3-YLPYRIMIDIN-2-YL)AMINO]PIPERIDIN-1-YL}-N-METHYLACETAMIDE3cgoAA91
3ELN-{4-[(3-{2-[(TRANS-4-AMINOCYCLOHEXYL)AMINO]PYRIMIDIN- 4-YL}PYRIDIN-2-YL)OXY]NAPHTHALEN-1- YL}BENZENESULFONAMIDE4u79AA91 E111 I124 L206 D207
984CYCLOPROPYL-{4-[5-(3,4-DICHLOROPHENYL)-2-[(1-METHYL)-PIPERIDIN]-4-YL-3-PROPYL-3H-IMIDAZOL-4-YL]-PYRIMIDIN-2-YL}AMINE1pmnAA91 I124 L206
JNK4-METHOXY-CYCLOHEXANECARBOXYLIC ACID [2'-(4-FLUORO-PHENYLAMINO)-[4,4'] BIPYRIDINYL-2-YL]-AMIDE2excXA91 I124 L206
SNB1-(3-BROMOPHENYL)-7-CHLORO-6-METHOXY-3,4-DIHYDROISOQUINOLINE2wajAA91 I124 L206
3HQ3-(4-{[(4-METHYLPHENYL)CARBAMOYL]AMINO}-1H-PYRAZOL-1- YL)-N-(2-METHYLPYRIDIN-4-YL)BENZAMIDE4w4yAA91 I124 L206
J67(3Z)-1-[(6-FLUORO-4H-1,3-BENZODIOXIN-8-YL)METHYL]-4-[(E)-2-PHENYLETHENYL]-1H-INDOLE-2,3-DIONE 3-OXIME3g9lXA91 I124 N152
880CYCLOHEXYL-{4-[5-(3,4-DICHLOROPHENYL)-2-PIPERIDIN-4-YL-3-PROPYL-3H-IMIDAZOL-4-YL]-PYRIMIDIN-2-YL}AMINE1pmqAA91 I124 N152 L206
AIZ3-{6-[(2-CHLOROPHENYL)AMINO]-1H-INDAZOL-3-YL}-5-{[4-(DIMETHYLAMINO)BUTANOYL]AMINO}BENZOIC ACID2b1pAA91 I124 N152 L206
J074-{[5-CHLORO-4-(1H-INDOL-3-YL)PYRIMIDIN-2-YL]AMINO}-N-ETHYLPIPERIDINE-1-CARBOXAMIDE2p33AA91 I124 N152 L206
JK13-(4-(3-PHENYLUREIDO)-1H-PYRAZOL-1-YL)-N-(3,4,5-TRIMETHOXYPHENYL)BENZAMIDE3fi2AA91 I124 N152 L206
JK23-{5-[(2-FLUOROPHENYL)AMINO]-1H-INDAZOL-1-YL}-N-(3,4,5-TRIMETHOXYPHENYL)BENZAMIDE3fi3AA91 I124 N152 L206
J72(3E)-5-FLUORO-1-[(6-FLUORO-4H-1,3-BENZODIOXIN-8-YL)METHYL]-1H-INDOLE-2,3-DIONE 3-OXIME3g90XA91 I124 N152 L206
JBI9-CYCLOPENTYL-N~8~-(2-FLUOROPHENYL)-N~2~-(4-METHOXYPHENYL)-9H-PURINE-2,8-DIAMINE3ttjAA91 I124 N152 L206
1RQCYCLOPROPYL[(3R)-3-({4-[6-HYDROXY-2-(NAPHTHALEN-2-YL)- 1H-BENZIMIDAZOL-1-YL]PYRIMIDIN-2-YL}AMINO)PIPERIDIN-1- YL]METHANONE4kkhAA91 I124 N152 L206
3HJN-(2-METHYLPYRIDIN-4-YL)-3-{4-[(PHENYLCARBAMOYL)AMINO]- 1H-PYRAZOL-1-YL}BENZAMIDE4w4wAA91 I124 N152 L206
5191-(TRANS-4-{[7-OXO-8-(PROPAN-2-YL)-7,8-DIHYDROPYRIDO[2, 3-D]PYRIMIDIN-2-YL]AMINO}CYCLOHEXYL)-3-PROPAN-2-YLUREA4y5hAA91 I124 N152 L206
880CYCLOHEXYL-{4-[5-(3,4-DICHLOROPHENYL)-2-PIPERIDIN-4-YL-3-PROPYL-3H-IMIDAZOL-4-YL]-PYRIMIDIN-2-YL}AMINE4z9lAA91 I124 N152 L206
5372,6-DIHYDROANTHRA/1,9-CD/PYRAZOL-6-ONE1pmvAA91 L206
BZ9N-[3-METHYL-4-({3-[2-(METHYLAMINO)PYRIMIDIN-4-YL]PYRIDIN-2-YL}OXY)NAPHTHALEN-1-YL]-1H-BENZIMIDAZOL-2-AMINE3da6AA91 L95 E111 I124 L206
5895-[2-(CYCLOHEXYLAMINO)PYRIDIN-4-YL]-4-NAPHTHALEN-2-YL-2-(TETRAHYDRO-2H-PYRAN-4-YL)-2,4-DIHYDRO-3H-1,2,4-TRIAZOL-3-ONE3oy1AA91 M115 I124 N152 L206
KBITRANS-4-({9-[(3S)-TETRAHYDROFURAN-3-YL]-8-[(2,4,6-TRIFLUOROPHENYL)AMINO]-9H-PURIN-2-YL}AMINO)CYCLOHEXANOL3ttiAA91 M115 I124 N152 L206
C0MN-{3-CYANO-6-[3-(1-PIPERIDINYL)PROPANOYL]-4,5,6,7-TETRAHYDROTHIENO[2,3-C]PYRIDIN-2-YL}1-NAPHTHALENECARBOXAMIDE2o0uAA91 M115 L206
CQQ4-{[4-(DIMETHYLAMINO)BUTANOYL]AMINO}-N-(3-{[4-(PYRIDIN-3-YL)PYRIMIDIN-2-YL]AMINO}PHENYL)BENZAMIDE3v6rAA91 N152 C154 L206
CQQ4-{[4-(DIMETHYLAMINO)BUTANOYL]AMINO}-N-(3-{[4-(PYRIDIN-3-YL)PYRIMIDIN-2-YL]AMINO}PHENYL)BENZAMIDE3v6rBA91 N152 C154 L206
0F03-{[4-(DIMETHYLAMINO)BUTANOYL]AMINO}-N-(4-{[4-(PYRIDIN-3-YL)PYRIMIDIN-2-YL]AMINO}PHENYL)BENZAMIDE3v6sBA91 N152 C154 L206
738N-(3-CYANO-4,5,6,7-TETRAHYDRO-1-BENZOTHIEN-2-YL)-2-FLUOROBENZAMIDE2o2uAA91 N152 L206
46C4-[(6-CHLORO-1-OXO-4-PHENYL-3-PROPANOYLISOQUINOLIN-2(1H)-YL)METHYL]BENZOIC ACID2zdtAA91 N152 L206
JNFN-CYCLOHEXYL-4-IMIDAZO[1,2-A]PYRIDIN-3-YL-N-METHYLPYRIMIDIN-2-AMINE3cgfAA91 N152 L206
JK35-BROMO-N-(3-CHLORO-2-(4-(PROP-2-YNYL)PIPERAZIN-1-YL)PHENYL)FURAN-2-CARBOXAMIDE3fv8AA91 N152 L206
SYYMETHYL 3-[(2-THIOPHEN-2-YLACETYL)AMINO]THIOPHENE-2-CARBOXYLATE3oxiAA91 N152 L206
932N-[4-METHYL-3-(1H-1,2,4-TRIAZOL-5-YL)THIOPHEN-2-YL]-2-(2-OXO-3,4-DIHYDROQUINOLIN-1(2H)-YL)ACETAMIDE3ptgAA91 N152 L206
34IN-[4-CYANO-3-(1H-1,2,4-TRIAZOL-5-YL)THIOPHEN-2-YL]-2- (2-OXO-3,4-DIHYDROQUINOLIN-1(2H)-YL)ACETAMIDE3rtpAA91 N152 L206
AMPAMP4kkeAA91 N152 L206
4F21-{TRANS-4-[(8-CYCLOPENTYL-7-OXO-7,8-DIHYDROPYRIDO[2,3- D]PYRIMIDIN-2-YL)AMINO]CYCLOHEXYL}-3-PROPAN-2-YLUREA4y46AA91 N152 L206
3WHN-ETHYL-4-{[4-(1H-INDOL-3-YL)-5-IODOPYRIMIDIN-2- YL]AMINO}PIPERIDINE-1-CARBOXAMIDE4x21AA91 N152 L206
3WHN-ETHYL-4-{[4-(1H-INDOL-3-YL)-5-IODOPYRIMIDIN-2- YL]AMINO}PIPERIDINE-1-CARBOXAMIDE4x21BA91 N152 L206
ANPAMP-PNP4z9lAC154
IIIPeptide ligand (PRO,LYS,ARG,PRO,THR,THR,LEU,ASN,LEU,PHE)3oxiAE367
IIIPeptide ligand (PRO,LYS,ARG,PRO,THR,THR,LEU,ASN,LEU,PHE)4h39AE367
IIIPeptide ligand (VAL,VAL,ARG,PRO,GLY,SER,LEU,ASP,LEU,PRO)4h3bAE367
IIIPeptide ligand (VAL,VAL,ARG,PRO,GLY,SER,LEU,ASP,LEU,PRO)4h3bCE367
TFATRIFLUOROACETYL GROUP2r9sBL206
TFATRIFLUOROACETYL GROUP2r9sAN152 L206
255N-(TERT-BUTYL)-4-[5-(PYRIDIN-2-YLAMINO)QUINOLIN-3-YL]BENZENESULFONAMIDE2r9sBN89 A91 I124 N152 L206
3NL3-(4-{[(2-CHLOROPHENYL)CARBAMOYL]AMINO}-1H-PYRAZOL-1- YL)-N-{1-[(3S)-PYRROLIDIN-3-YL]-1H-PYRAZOL-4- YL}BENZAMIDE4whzAN89 A91 I124 N152 L206
ANPAMP-PNP1pmqAQ75
3HN3-(4-{[(4-FLUOROPHENYL)CARBAMOYL]AMINO}-1H-PYRAZOL-1- YL)-N-(2-METHYLPYRIDIN-4-YL)BENZAMIDE4w4xAQ75 A91 I124 L206
3H83-(4-{[(2-CHLOROPHENYL)CARBAMOYL]AMINO}-1H-PYRAZOL-1- YL)-N-(2-METHYLPYRIDIN-4-YL)BENZAMIDE4w4vAQ75 A91 I124 N152 L206
9HP9-(4-HYDROXYPHENYL)-2,7-PHENANTHROLINE1pmuAQ75 A91 L206
0F03-{[4-(DIMETHYLAMINO)BUTANOYL]AMINO}-N-(4-{[4-(PYRIDIN-3-YL)PYRIMIDIN-2-YL]AMINO}PHENYL)BENZAMIDE3v6sAQ75 A91 N152 C154 L206
ANPAMP-PNP1jnkAQ75 A91 N152 L206
FMYN-[(2Z)-4-(3-FLUORO-5-MORPHOLIN-4-YLPHENYL)PYRIMIDIN-2(1H)-YLIDENE]-4-(3-MORPHOLIN-4-YL-1H-1,2,4-TRIAZOL-1-YL)ANILINE3kvxAQ75 A91 N152 L206
IIIPeptide ligand (PRO,LYS,ARG,PRO,THR,THR,LEU,ASN,LEU,PHE)3ptgAY171 E367


Top
Conservation information for LBS of MAPK10
Multiple alignments for P53779 in multiple species
LBSAA sequence# speciesSpecies


Copyright © 2016-Present - The University of Texas Health Science Center at Houston
Site Policies | State of Texas